Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2 Multiple-indication Biomarker, Safety, and Efficacy Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

NCT07280377 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT07280377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07280377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2 Multiple-indication Biomarker, Safety, and Efficacy Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Lead sponsor
Oncolytics Biotech
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 27, 2021
Completion date
December 31, 2028
Enrollment
122 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer metastatic, pancreatic cancer metastatic, squamous cell carcinoma of the anus stage unspecified, unresectable pancreatic carcinoma